Hernández-Pedro Norma, Granados-Soto Vinicio, Ordoñez Graciela, Pineda Benjamin, Rangel-López Edgar, Salazar-Ramiro Aleli, Arrieta Oscar, Sotelo Julio
Neuroimmunology Unit, Instituto Nacional de Neurología y Neurocirugía (INNN), Mexico City, Mexico.
Departamento de Farmacobiología, Centro de Investigación y Estudios Avanzados (CINVESTAV) Sede Sur, Mexico City, Mexico.
Transl Res. 2014 Sep;164(3):196-201. doi: 10.1016/j.trsl.2014.04.002. Epub 2014 Apr 8.
All-trans retinoic acid (ATRA) promotes the endogenous expression of both nerve growth factor (NGF) and retinoic acid receptor beta (RAR-β). We have previously shown that the administration of ATRA partly reverts the damage induced by diabetic neuropathy (DN). In this investigation, we evaluated the effects of vitamin A, a commercial, inexpensive compound of retinoic acid, on the therapy of DN. A total of 70 rats were randomized into 4 groups. Group A was the control, and groups B, C, and D received a total dose of 60 mg/kg streptozotocin intraperitoneally. When signs of DN developed, groups C and D were treated either with vitamin A (20,000 IU) or with ATRA 25 mg/kg for 60 days. Plasma glucose, contents of NGF, thermal and nociceptive tests, and RAR-β expression were evaluated. All diabetic rats developed neuropathy. The treatment with vitamin A and ATRA reverted similarly the sensorial disturbances, which was associated with increased contents of NGF and RAR-β expression. Our results indicate that the administration of vitamin A has the same therapeutic effect as ATRA on peripheral neuropathy and suggest its potential therapeutic use in patients with diabetes.
全反式维甲酸（ATRA）可促进神经生长因子（NGF）和维甲酸受体β（RAR-β）的内源性表达。我们之前已经表明，给予ATRA可部分逆转糖尿病性神经病变（DN）所致的损伤。在本研究中，我们评估了维生素A（一种商业化的、价格低廉的维甲酸化合物）对DN治疗的效果。总共70只大鼠被随机分为4组。A组为对照组，B、C、D组腹腔注射60 mg/kg链脲佐菌素。当出现DN体征时，C组和D组分别用维生素A（20,000 IU）或ATRA 25 mg/kg治疗60天。评估血浆葡萄糖、NGF含量、热觉和痛觉测试以及RAR-β表达。所有糖尿病大鼠均出现神经病变。维生素A和ATRA治疗同样逆转了感觉障碍，这与NGF含量增加和RAR-β表达有关。我们的结果表明，给予维生素A对外周神经病变具有与ATRA相同的治疗效果，并提示其在糖尿病患者中的潜在治疗用途。
